Posted by Michael Wonder on 27 Apr 2024
Pierre Fabre Laboratories receive positive CHMP opinion for Obgemsa (vibegron) in overactive bladder syndrome
26 April 2024 - Pierre Fabre Laboratories announced that the CHMP of the EMA has adopted a positive opinion recommending approval of Obgemsa (vibegron) for the symptomatic treatment of adult patients with overactive bladder syndrome.
Pierre Fabre Laboratories acquired an exclusive license from Urovant Sciences to register and commercialise vibegron in the European Economic Area in 2022.
